SCHEMBL23043972

SCHEMBL23043972

Cc1ccc(CC(=O)Nc2ccc(-c3cn(C)c4ncnc(N)c34)c(C)c2)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ EIF2AK3 Q9NZJ5 6/20 0.52
▸ NTRK1 P04629 4/20 0.47
▸ RIPK1 Q13546 2/20 0.46
▸ FLT3 P36888 2/20 0.44
▸ EIF2S1 P05198 1/20 0.43
▸ AXL P30530 2/20 0.43
▸ MET P08581 1/20 0.43
▸ NTRK2 Q16620 3/20 0.42
▸ KCNH2 Q12809 2/20 0.42
▸ NTRK3 Q16288 1/20 0.42
▸ RORC P51449 2/20 0.42
▸ KDR P35968 3/20 0.41
▸ NLRP3 Q96P20 1/20 0.41
▸ PLK4 O00444 1/20 0.41
▸ AURKA O14965 1/20 0.41
▸ DYRK3 O43781 1/20 0.41
▸ ROCK2 O75116 1/20 0.41
▸ RPS6KA5 O75582 1/20 0.41
▸ PRKD3 O94806 1/20 0.41
▸ MAP4K4 O95819 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29747011 1.00 EIF2AK3 (0.52) EIF2AK3NTRK1RIPK1FLT3EIF2S1
SCHEMBL23043982 0.94 EIF2AK3 (0.46) EIF2AK3NTRK1RIPK1FLT3EIF2S1
SCHEMBL29746633 0.94 EIF2AK3 (0.46) EIF2AK3NTRK1RIPK1FLT3EIF2S1
SCHEMBL29746534 0.93 EIF2AK3 (0.52) EIF2AK3NTRK1RIPK1FLT3AXL
SCHEMBL23043902 0.93 NTRK1 (0.51) EIF2AK3NTRK1RIPK1FLT3EIF2S1
SCHEMBL29746677 0.93 NTRK1 (0.51) EIF2AK3NTRK1RIPK1FLT3EIF2S1
SCHEMBL23044044 0.93 EIF2AK3 (0.52) EIF2AK3NTRK1RIPK1FLT3AXL
SCHEMBL23044049 0.93 EIF2AK3 (0.51) EIF2AK3NTRK1RIPK1FLT3EIF2S1
SCHEMBL29746539 0.93 EIF2AK3 (0.51) EIF2AK3NTRK1RIPK1FLT3EIF2S1
SCHEMBL23043988 0.91 MAPT (0.49) EIF2AK3NTRK1RIPK1EIF2S1NLRP3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220356186-A1 PERK INHIBITING PYRROLOPYRIMIDINE COMPOUNDS HIBERCELL, INC. 2022-11-10 — — US claimed
EP-4021908-A1 PERK INHIBITING PYRROLOPYRIMIDINE COMPOUNDS Hibercell, Inc. (US) 2022-07-06 — — EP claimed
CN-114710956-A PERK-INHIBITING PYRROLOPYRIMIDINE COMPOUNDS 希伯塞尔股份有限公司 2022-07-05 — — CN claimed
WO-2021231788-A1 PERK INHIBITING PYRROLOPYRIMIDINE COMPOUNDS TO TREAT VIRAL INFECTIONS HIBERCELL, INC. (US) 2021-11-18 — — WO claimed
WO-2021041975-A1 PERK INHIBITING PYRROLOPYRIMIDINE COMPOUNDS HIBERCELL, INC. (US) 2021-03-04 — — WO claimed
US-20220356186-A1 PERK INHIBITING PYRROLOPYRIMIDINE COMPOUNDS HIBERCELL, INC. 2022-11-10 — — US disclosed
EP-4021908-A1 PERK INHIBITING PYRROLOPYRIMIDINE COMPOUNDS Hibercell, Inc. (US) 2022-07-06 — — EP disclosed
CN-114710956-A PERK-INHIBITING PYRROLOPYRIMIDINE COMPOUNDS 希伯塞尔股份有限公司 2022-07-05 — — CN disclosed
WO-2021231788-A1 PERK INHIBITING PYRROLOPYRIMIDINE COMPOUNDS TO TREAT VIRAL INFECTIONS HIBERCELL, INC. (US) 2021-11-18 — — WO disclosed
WO-2021041975-A1 PERK INHIBITING PYRROLOPYRIMIDINE COMPOUNDS HIBERCELL, INC. (US) 2021-03-04 — — WO disclosed
WO-2021041975-A1 PERK INHIBITING PYRROLOPYRIMIDINE COMPOUNDS HIBERCELL, INC. (US) 2021-03-04 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220356186-A1 PERK INHIBITING PYRROLOPYRIMIDINE COMPOUNDS EEF2K, ATF4, MAPKAPK2 EIF2AK3 96/4885NTRK1 2842/4885RIPK1 451/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback